Stephenson Kathryn E
Center for Virology and Vaccine Research and Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 330 Brookline E/CLS-1037, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Infect Dis Clin North Am. 2025 Jun;39(2):253-274. doi: 10.1016/j.idc.2025.02.003. Epub 2025 Mar 15.
Current coronavirus disease 2019 (COVID-19) vaccines have prevented millions of deaths since the beginning of the pandemic. Yet, current vaccines have critical limitations: (1) they elicit poor mucosal immune responses with reduced protection against infection and viral transmission, (2) immune responses wane quickly, and (3) new immune evasive severe acute respiratory syndrome coronavirus 2 variants continue to emerge. Next-generation vaccines aim to induce improved mucosal immunity via mucosal administration, and to elicit a greater duration and breadth of immune responses through new platforms like self-amplifying RNA. This review focuses on next-generation COVID-19 vaccines that have publicly available clinical data and are most likely to proceed in further development.
自新冠疫情开始以来,目前的2019冠状病毒病(COVID-19)疫苗已预防了数百万人死亡。然而,目前的疫苗存在关键局限性:(1)它们引发的黏膜免疫反应较差,对感染和病毒传播的保护作用降低;(2)免疫反应迅速减弱;(3)新的免疫逃逸严重急性呼吸综合征冠状病毒2变种不断出现。下一代疫苗旨在通过黏膜给药诱导更强的黏膜免疫,并通过自我扩增RNA等新平台引发更持久、更广泛的免疫反应。本综述重点关注已公开临床数据且最有可能进一步研发的下一代COVID-19疫苗。